Chiorean et al. in a phase I study evaluated the safety and efficacy effects of sorafenib with gemcitabine-based chemoradiotherapy in locally advanced pancreatic adenocarcinoma, through pharmacodynamics analysis of tumor perfusion and vascularity and analysis of VEGFA and VEGFR2 single nucleotide gene polymorphisms [59]. The gene discussed is VEGFA; the disease is neoplasm.